CERTIVOS VERIFIED
API Workshop
Manufacturer QC
- Purity
- 98.9%
- Method
- HPLC
TJZ8W5YJBXWQ
In Stock
1
$44.99 CAD10,875 successful visitors
No crypto required. Pay with Visa, Mastercard, Amex, Apple Pay, Google Pay, or Interac.
For in vitro laboratory research use only. Not for human consumption. All products are supplied strictly for in vitro laboratory research use only. Not drugs, foods, supplements, or cosmetics. Not evaluated by Health Canada or the FDA.
Dose per Vial
5mg
Sold As
Single vial
Form
Lyophilized powder
Storage
2–8°C
Price
$44.99 CAD
GLP-1 receptor agonist. 5mg lyophilized powder per vial.
VERIFICATION — Batch CP-030-20260813
All compounds independently tested and verifiedLab results →
Research
Semaglutide
What It Is
Semaglutide is a GLP-1 receptor agonist — a compound that mimics a gut hormone your body naturally produces after eating. It's 94% identical to the natural version but engineered to last about a week instead of minutes. Originally developed for blood sugar management, it became the most talked-about weight loss compound after clinical trials showed unprecedented results.
How It Works
When you eat, your gut releases GLP-1 to signal fullness. Semaglutide does the same thing but much stronger and longer. It tells your brain you're full (reducing appetite), slows stomach emptying (so you feel satisfied longer), and improves how your body handles insulin. The long-lasting effect comes from a fatty acid chain that lets it hitch a ride on albumin in your blood.
What The Research Shows
01
Clinical trials (STEP program) showed average weight loss of 15–17% over 68 weeks — that's roughly 35-40 lbs for a 230 lb person.
02
The SELECT trial showed a 20% reduction in heart attacks and strokes in people with existing cardiovascular disease.
03
Head-to-head comparisons confirmed semaglutide outperforms older GLP-1 drugs like liraglutide for both weight and blood sugar outcomes.
04
Effects are dose-dependent — higher doses produce more weight loss but also more GI side effects (nausea, mainly in the first few weeks).
Sources
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH et al. — N Engl J Med, 2021 · PubMed
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM et al. — N Engl J Med, 2023 · PubMed
Information derived from published preclinical and clinical research. Provided for educational purposes only — not medical advice.
Customer Reviews
- Ryan K.★★★★★
Customer service is top notch and fast delivery!
- Jamie★★★★★
Had my order confirmation instantly, shipping information within hours and product delivered in 2 business days.
- Jessica T.★★★★★
Great communication when a product came back in stock and even got a free bottle of bac water!
- Sanjiv R.★★★★★
Product quality is the best and had it delivered to my office within 72 hours of ordering.